SYS6023 combination therapy for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed advanced or metastatic breast cancer that has progressed despite recent treatment
- Provide a tumor tissue sample for HER3 testing
- At least one measurable tumor visible on imaging
- Good overall health status (ECOG score 0–1, meaning able to do most daily activities)
- Expected to survive at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced hormone-positive, HER2-negative breast cancer that has worsened after CDK4/6 inhibitor treatment. The goal is to see if this combination can slow cancer growth for a longer time.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.